We have developed a semi-automated method for the large-scale production of high mammal pancreatic islet containing microcapsules, comprised of alginic acid and aminoacidic polycations. We have been able to scale-up procedures originally developed for rodent islets and render them suitable for bulk, high mammal islet microencapsulation. Physical/chemical properties of these microcapsules, fabricated on a large-scale basis, were shown not to adversely affect the long-term in vitro retention of islet morphologic integrity, viability and function. Transplantation of human islets, encapsulated by this method, into non-immunosuppressed, spontaneously diabetic rodents or dogs resulted in a substantial reversal of hyperglycaemia, which was either partial or complete, demonstrating suitability of this procedure for in vivo clinical application. The procedure may offer the opportunity to immunoprotect large-size mammalian islet grafts with no requirement for immunosuppression of the recipients and, eventually, to employ non-human tissue as a source of donor islets.

A method for the large scale production of microencapsulated islets: in vitro and in vivo results

CALAFIORE, Riccardo;FALORNI, Alberto;
1992

Abstract

We have developed a semi-automated method for the large-scale production of high mammal pancreatic islet containing microcapsules, comprised of alginic acid and aminoacidic polycations. We have been able to scale-up procedures originally developed for rodent islets and render them suitable for bulk, high mammal islet microencapsulation. Physical/chemical properties of these microcapsules, fabricated on a large-scale basis, were shown not to adversely affect the long-term in vitro retention of islet morphologic integrity, viability and function. Transplantation of human islets, encapsulated by this method, into non-immunosuppressed, spontaneously diabetic rodents or dogs resulted in a substantial reversal of hyperglycaemia, which was either partial or complete, demonstrating suitability of this procedure for in vivo clinical application. The procedure may offer the opportunity to immunoprotect large-size mammalian islet grafts with no requirement for immunosuppression of the recipients and, eventually, to employ non-human tissue as a source of donor islets.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/1031277
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact